Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022ĮMA's CHMP recommended extending the use of Evusheld to include treating adults and adolescents with COVID-19 who do not require supplemental oxygenĮMA's CHMP recommended authorising the use of Comirnaty as a booster dose for children aged 5 to 11ĮMA's CHMP recommended converting the conditional marketing authorisations for Comirnaty and Spikevax to standard marketing authorisationsĮMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccinesĮMA is holding a regular press briefing on COVID-19 and monkeypox, on Tuesday 20 September 2022ĮMA's CHMP approved a new manufacturing site for the active substance of COVID-19 Vaccine ValnevaĬOVID-19 Vaccine (inactivated, adjuvanted) Valneva The video recording is available of EMA's latest COVID-19 and monkeypox press briefingĮMA regular press briefing on COVID-19 and monkeypoxĮMA's CHMP recommended extending the use of Veklury to include treating children with COVID-19 needing supplemental oxygen, or risking severe disease Spikevax (previously COVID-19 Vaccine Moderna) The European Commission authorised the conversion of the conditional marketing authorisation for Spikevax to standard marketing authorisationĮMA published the assessment report for Veklury supporting its extension of indication to include children with COVID-19 who need supplemental oxygen, or are at risk of severe diseaseĮMA started a rolling review for the use of an adapted version of Comirnaty in children aged 5 to 11ĮMA's CHMP started evaluating an application for the authorisation of an additional adapted version of Spikevax The European Commission issued a decision renewing the conditional marketing authorisation for NuvaxovidĮMA published updated product information for COVID-19 treatment Paxlovid, with an increase in its approved shelf life The European Commission authorised the conversion of the conditional marketing authorisation for Comirnaty to standard marketing authorisation Vaxzevria (previously COVID-19 Vaccine AstraZeneca)ĮMA published updated product information for Vaxzevria, with an increase in its approved shelf life

EMA's CHMP recommended converting the conditional marketing authorisation for Vaxzevria to standard marketing authorisation

Covid vaccine update